The project aims to study the impact of SGLT2i therapy on clinical and biochemical aspects. in elderly. The project will combine different types of data, such as clinical and biological information, and will use advanced Bayesian statistical methods to understand the relationship between risk factors and patient outcomes following treatment with SGLT2 inhibitors.
Eligibility
Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Participant is willing and able to give informed consent for participation in the study;
2. Patients must be enrolled also in MED-Cli e MED-Mol studies by signing both the MED-Cli e MED-Mol informed consents.
3. The medical product is the standard of care for the patient and has been prescribed according to clinical practice and independent of the present study;
4. Age ≥65 years;
5. Participant has not yet started the prescribed SGLT2i therapy;
6. Participant has at least one clinical indication for SGLT2i use according to clinical practice guidelines.
Exclusion Criteria:
1. Current or previous use of SGLT2i;
2. Inability to sign the informed consent.
Primary outcome measure(s)
Patient health status prior and after 6 months of SGLT2i therapy through Frailty Index variation (FI) — From enrollment to 6 months Patient health status prior and after 6 months of SGLT2i therapy through Frailty Index variation (FI).
The FI is score measured by comparing the ratio of health deficits present within an individual to possible health deficits, using a pre-specified list of 30 or more deficits.
Deficits included in the model will be collected during the visit trough questionnaires and clinical and biochemical evaluation
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
